LAM Therapeutics Announces Progress of its Clinical Portfolio with FDA Clearance of New Trial in Leukemia and Advancement of Clinical Trial in Lymphoma
Collaboration announced for combination study with atezolizumab in non-Hodgkin B-cell lymphoma
GUILFORD, Conn.—Nov. 30, 2017– LAM Therapeutics (LAM), a 4Catalyzer company, advanced its clinical portfolio with the U.S. Food and Drug Administration (FDA) clearance of LAM’s Investigational New Drug (IND) application for LAM-003 in leukemia patients. LAM-002 has transitioned into Phase 2 […]